CEDOES - Diagnóstico e Pesquisa

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Lupus (SLE)3 trials
• Liver and biliary tract cancer1 trial
• Metastatic breast cancer1 trial
• Multiple sclerosis1 trial

Phase

• Phase 35 trials
• Phase 2/31 trial

Status

• Active, not recruiting4 trials
• Completed1 trial
• Enrolling by invitation1 trial

Lead sponsor

• Biogen3 trials
• Hoffmann-La Roche3 trials

Running trials

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

  NCT06065748· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)

  NCT05904886· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus

  NCT05531565· Phase 2/3· Biogen· Source

• Enrolling by invitation

  A Study to Learn More About the Long-Term Safety of Litifilimab (BIIB059) Injections and it's Effects on Symptoms in Adults With Systemic Lupus Erythematosus (SLE)

  NCT05352919· Phase 3· Biogen· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04895241· Phase 3· Biogen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lupus (SLE)1 recruiting

Closed trials

• Completed

  A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis

  NCT05232825· Phase 3· Hoffmann-La Roche· Source